%0 Book Section
%A Rodrigues, FB
%A Byrne, LM
%A Wild, EJ
%B Huntington’s Disease
%C New York, NY, USA
%D 2018
%E Precious, SV
%E Rosser, AE
%E Dunnett, SB
%F discovery:10049810
%I Humana Press
%K Biomarkers, Blood, Cerebrospinal fluid, Huntington’s disease, Review, Urine, Biomarkers, Body Fluids, Brain, Drug Development, Humans, Huntingtin Protein, Huntington Disease, Inflammation Mediators, Neurons, Neurotransmitter Agents, Oxidative Stress, Proteomics, Transglutaminases
%P 329-396
%S Methods in Molecular Biology book series
%T Biofluid Biomarkers in Huntington's Disease
%U https://discovery.ucl.ac.uk/id/eprint/10049810/
%V 1780
%X Huntington's disease (HD) is a chronic progressive neurodegenerative condition where new markers of disease progression are needed. So far no disease-modifying interventions have been found, and few interventions have been proven to alleviate symptoms. This may be partially explained by the lack of reliable indicators of disease severity, progression, and phenotype.Biofluid biomarkers may bring advantages in addition to clinical measures, such as reliability, reproducibility, price, accuracy, and direct quantification of pathobiological processes at the molecular level; and in addition to empowering clinical trials, they have the potential to generate useful hypotheses for new drug development.In this chapter we review biofluid biomarker reports in HD, emphasizing those we feel are likely to be closest to clinical applicability.
%Z This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.